Document is current
Any future updates will be listed below
-
Authors
Hurvitz, Sara A.
Caswell-Jin, Jennifer L. http://orcid.org/0000-0002-5711-8355
McNamara, Katherine L. http://orcid.org/0000-0002-3717-6494
Zoeller, Jason J.
Bean, Gregory R. http://orcid.org/0000-0003-2866-8283
Dichmann, Robert
Perez, Alejandra
Patel, Ravindranath
Zehngebot, Lee
Allen, Heather
Bosserman, Linda
DiCarlo, Brian
Kennedy, April
Giuliano, Armando
Calfa, Carmen
Molthrop, David
Mani, Aruna
Chen, Hsiao-Wang
Dering, Judy
Adams, Brad
Kotler, Eran
Press, Michael F.
Brugge, Joan S. http://orcid.org/0000-0002-2547-4814
Curtis, Christina http://orcid.org/0000-0003-0166-3802
Slamon, Dennis J.
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-11-1-0572)
StandUp To Cancer-American Association for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA182514)
Breast Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 28 July 2020
Accepted: 15 October 2020
First Online: 17 November 2020
Competing interests
: S.H. received contracted research and medical writing assistance from Ambrx, Amgen, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, Puma, Radius, Sanofi, Seattle Genetics, and Dignitana. A.P. received institutional research support from Genentech, AstraZeneca, Immunomedics, Nektar, and Macrogenics. L.B. received honoraria from and/or was on the speaker bureau for AstraZeneca, Pfizer, Merck, Puma, Novartis, GlaxoSmithKline, Amgen, Johnson & Johnson, Genentech/Roche, Sandoz, Dendreon, and Genomic Health, and performed consulting work for Integra Connect and Anthem Blue Cross. A.M. is employed by Genentech/Roche and owns stock in Roche. M.P. received research support from Cepheid, was on the Scientific Advisory Board and received research support from Eli Lilly, Zymeworks, and Novartis, was a consultant for and received research support from Puma, and was on the Scientific Advisory Board for Biocartis. C.C. is a scientific advisor to GRAIL and reports stock options as well as consulting for GRAIL and Genentech. D.S. received research funding from Pfizer, Novartis, Syndax, Millenium Pharmaceuticals, Aileron Therapeutics, Bayer, and Genentech, owned stock in Biomarin, Amgen, Seattle Genetics, and Pfizer, served on the Board of Directors for BioMarin, and performed consulting/advisory board work for Eli Lilly, Novartis, Bayer, and Pfizer. The remaining authors declare no competing interests.
